GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Other Assets for Insurance Companies

Adaptive Biotechnologies (FRA:1HM) Other Assets for Insurance Companies


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Other Assets for Insurance Companies?

Other Assets for Insurance Companies only applies to insurance companies.


Adaptive Biotechnologies (FRA:1HM) Business Description

Industry
Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").